

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

An Abstract of the Invention has been added.

In the claims:

1. (Amended) A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound [(I)] and insulin, to a mammal in need thereof.
3. (Amended) A method according to [claim 1or] claim 2, which comprises the administration of 2 to 12 mg of Compound (I).
4. (Amended) A method according to [any one of] claim[s 1 to] 3, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).
5. (Amended) A method according to [any one of] claim[s 1 to 3] 4, which comprises the administration of 2 to 4mg of Compound (I).
6. (Amended) A method according to [any one of] claim[s 1 to 3] 4, which comprises the administration of 4 to 8mg of Compound (I).
7. (Amended) A method according to [any one of] claim[s 1 to 3] 4, which comprises the administration of 8 to 12 mg of Compound (I).
8. (Amended) A method according to [any one of] claim[s 1 to 3] 5, which comprises the administration of 2 mg of Compound (I).
9. (Amended) A method according to [any one of] claim[s 1 to 3] 5, which comprises the administration of 4 mg of Compound (I).
10. (Amended) A method according to [any one of] claim[s 1 to 3] 6, which comprises the administration of 8 mg of Compound (I).

09928326-081301

11. (Amended) A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound [(II), insulin and a pharmaceutically acceptable carrier therefor.

13. (Amended) A composition according to claim 11 [or claim 12], which comprises up to 12 mg or 2 to 12 mg of Compound (I).

09928326-081301